Search

Your search keyword '"Kluin, P"' showing total 1,167 results
Start Over Author "Kluin, P"
1,167 results on '"Kluin, P"'

1. Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials

Author

Khouja, Mouhamad, Jiang, Linmiao, Pal, Karol, Stewart, Peter James, Regmi, Binaya, Schwarz, Martin, Klapper, Wolfram, Alig, Stefan K., Darzentas, Nikos, Kluin-Nelemans, Hanneke C., Hermine, Olivier, Dreyling, Martin, Gonzalez de Castro, David, Hoster, Eva, and Pott, Christiane

Published
2024
Full Text
View/download PDF

3. Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials

Author

Juul, Sidsel J., Rossetti, Sára, Aleman, Berthe M. P., van Leeuwen, Flora E., van der Kaaij, Marleen A. E., Giusti, Francesco, Meijnders, Paul, Raemaekers, John M. M., Kluin-Nelemans, Hanneke C., Spina, Michele, Krzisch, Daphne, Bigenwald, Camille, Stamatoullas, Aspasia, André, Marc, Plattel, Wouter J., Hutchings, Martin, and Maraldo, Maja V.

Published
2024
Full Text
View/download PDF

5. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status

Author

Wang, Yuwei, Dackus, Gwen M. H. E., Rosenberg, Efraim H., Cornelissen, Sten, de Boo, Leonora W., Broeks, Annegien, Brugman, Wim, Chan, Terry W. S., van Diest, Paul J., Hauptmann, Michael, ter Hoeve, Natalie D., Isaeva, Olga I., de Jong, Vincent M. T., Jóźwiak, Katarzyna, Kluin, Roelof J. C., Kok, Marleen, Koop, Esther, Nederlof, Petra M., Opdam, Mark, Schouten, Philip C., Siesling, Sabine, van Steenis, Charlaine, Voogd, Adri C., Vreuls, Willem, Salgado, Roberto F., Linn, Sabine C., and Schmidt, Marjanka K.

Published
2024
Full Text
View/download PDF

6. Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials

Author

Juul, Sidsel J., Rossetti, Sára, Kicinski, Michal, van der Kaaij, Marleen A. E., Giusti, Francesco, Meijnders, Paul, Aleman, Berthe M. P., Raemaekers, John M. M., Kluin-Nelemans, Hanneke C., Spina, Michele, Fermé, Christophe, Renaud, Loïc, Casasnovas, Olivier, Stamatoullas, Aspasia, André, Marc, Le Bras, Fabien, Plattel, Wouter J., Henry-Amar, Michel, Hutchings, Martin, and Maraldo, Maja V.

Published
2024
Full Text
View/download PDF

9. Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.

Author

Linder, Simon, Hoogstraat, Marlous, Stelloo, Suzan, Eickhoff, Nils, Schuurman, Karianne, de Barros, Hilda, Alkemade, Maartje, Bekers, Elise M, Severson, Tesa M, Sanders, Joyce, Huang, Chia-Chi Flora, Morova, Tunc, Altintas, Umut Berkay, Hoekman, Liesbeth, Kim, Yongsoo, Baca, Sylvan C, Sjöström, Martin, Zaalberg, Anniek, Hintzen, Dorine C, de Jong, Jeroen, Kluin, Roelof JC, de Rink, Iris, Giambartolomei, Claudia, Seo, Ji-Heui, Pasaniuc, Bogdan, Altelaar, Maarten, Medema, René H, Feng, Felix Y, Zoubeidi, Amina, Freedman, Matthew L, Wessels, Lodewyk FA, Butler, Lisa M, Lack, Nathan A, van der Poel, Henk, Bergman, Andries M, and Zwart, Wilbert

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Prostate Cancer, Aging, Urologic Diseases, Biotechnology, Cancer, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, 2.1 Biological and endogenous factors, Aetiology, ARNTL Transcription Factors, Androgens, Cell Line, Tumor, Circadian Rhythm, Drug Resistance, Neoplasm, Epigenomics, Humans, Male, Nitriles, Prostatic Neoplasms, Castration-Resistant, Receptors, Androgen, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

In prostate cancer, androgen receptor (AR)-targeting agents are very effective in various disease stages. However, therapy resistance inevitably occurs, and little is known about how tumor cells adapt to bypass AR suppression. Here, we performed integrative multiomics analyses on tissues isolated before and after 3 months of AR-targeting enzalutamide monotherapy from patients with high-risk prostate cancer enrolled in a neoadjuvant clinical trial. Transcriptomic analyses demonstrated that AR inhibition drove tumors toward a neuroendocrine-like disease state. Additionally, epigenomic profiling revealed massive enzalutamide-induced reprogramming of pioneer factor FOXA1 from inactive chromatin sites toward active cis-regulatory elements that dictate prosurvival signals. Notably, treatment-induced FOXA1 sites were enriched for the circadian clock component ARNTL. Posttreatment ARNTL levels were associated with patients' clinical outcomes, and ARNTL knockout strongly decreased prostate cancer cell growth. Our data highlight a remarkable cistromic plasticity of FOXA1 following AR-targeted therapy and revealed an acquired dependency on the circadian regulator ARNTL, a novel candidate therapeutic target.SignificanceUnderstanding how prostate cancers adapt to AR-targeted interventions is critical for identifying novel drug targets to improve the clinical management of treatment-resistant disease. Our study revealed an enzalutamide-induced epigenomic plasticity toward prosurvival signaling and uncovered the circadian regulator ARNTL as an acquired vulnerability after AR inhibition, presenting a novel lead for therapeutic development. See related commentary by Zhang et al., p. 2017. This article is highlighted in the In This Issue feature, p. 2007.

Published
2022

20. Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐CBFit)

Author

Ustun, Celalettin, Morgan, Elizabeth, Moodie, Erica EM, Pullarkat, Sheeja, Yeung, Cecilia, Broesby‐Olsen, Sigurd, Ohgami, Robert, Kim, Young, Sperr, Wolfgang, Vestergaard, Hanne, Chen, Dong, Kluin, Philip M, Dolan, Michelle, Mrózek, Krzysztof, Czuchlewski, David, Horny, Hans‐Peter, George, Tracy I, Kristensen, Thomas Kielsgaard, Ku, Nam K, Yi, Cecilia Arana, Møller, Michael Boe, Marcucci, Guido, Baughn, Linda, Schiefer, Ana‐Iris, Hilberink, JR, Pullarkat, Vinod, Shanley, Ryan, Kohlschmidt, Jessica, Coulombe, Janie, Salhotra, Amandeep, Soma, Lori, Cho, Christina, Linden, Michael A, Akin, Cem, Gotlib, Jason, Hoermann, Gregor, Hornick, Jason, Nakamura, Ryo, Deeg, Joachim, Bloomfield, Clara D, Weisdorf, Daniel, Litzow, Mark R, Valent, Peter, Huls, Gerwin, Perales, Miguel‐Angel, and Borthakur, Gautam

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Pediatric Research Initiative, Rare Diseases, Pediatric Cancer, Clinical Research, Childhood Leukemia, Pediatric, Stem Cell Research - Nonembryonic - Human, Stem Cell Research, Genetics, Hematology, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Chromosomes, Human, Pair 21, Chromosomes, Human, Pair 8, Core Binding Factors, Female, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Risk Factors, Severity of Illness Index, Translocation, Genetic, Young Adult, acute myeloid leukemia, core-binding factor, disease-free survival, KIT mutation, predictive value, relapse, scoring system, Biochemistry and Cell Biology, Oncology and carcinogenesis
Abstract

BackgroundAlthough the prognosis of core-binding factor (CBF) acute myeloid leukemia (AML) is better than other subtypes of AML, 30% of patients still relapse and may require allogeneic hematopoietic cell transplantation (alloHCT). However, there is no validated widely accepted scoring system to predict patient subsets with higher risk of relapse.MethodsEleven centers in the US and Europe evaluated 247 patients with t(8;21)(q22;q22).ResultsComplete remission (CR) rate was high (92.7%), yet relapse occurred in 27.1% of patients. A total of 24.7% of patients received alloHCT. The median disease-free (DFS) and overall (OS) survival were 20.8 and 31.2 months, respectively. Age, KIT D816V mutated (11.3%) or nontested (36.4%) compared with KIT D816V wild type (52.5%), high white blood cell counts (WBC), and pseudodiploidy compared with hyper- or hypodiploidy were included in a scoring system (named I-CBFit). DFS rate at 2 years was 76% for patients with a low-risk I-CBFit score compared with 36% for those with a high-risk I-CBFit score (P

Published
2018

21. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis

Author

Zanotti, Roberta, Bonifacio, Massimiliano, Lucchini, Giuseppe, Sperr, Wolfgang R., Scaffidi, Luigi, van Anrooij, Björn, Oude Elberink, Hanneke NC, Rossignol, Julien, Hermine, Olivier, Gorska, Aleksandra, Lange, Magdalena, Hadzijusufovic, Emir, Miething, Cornelius, Müller, Sabine, Perkins, Cecelia, Shomali, William, Elena, Chiara, Illerhaus, Anja, Jawhar, Mohamad, Parente, Roberta, Caroppo, Francesca, Solomianyi, Oleksii, Zink, Alexander, Mattsson, Mattias, Yavuz, Akif Selim, Panse, Jens, Varkonyi, Judit, Doubek, Michael, Sabato, Vito, Breynaert, Christine, Vucinic, Vladan, Schug, Tanja, Hägglund, Hans, Wortmann, Friederike, Brockow, Knut, Angelova-Fischer, Irena, Belloni Fortina, Anna, Triggiani, Massimo, Reiter, Andreas, Hartmann, Karin, Malcovati, Luca, Gotlib, Jason, Shoumariyeh, Khalid, Niedoszytko, Marek, Arock, Michel, Kluin-Nelemans, Hanneke C., Bonadonna, Patrizia, and Valent, Peter

Published
2022
Full Text
View/download PDF

22. Early Postoperative Changes in Von Willebrand Factor Activity Are Associated With Future Bleeding and Stroke in HeartMate 3 Patients

Author

Jahangiri, Parsa, Veen, Kevin M., van Moort, Iris, Bunge, Jeroen H., Constantinescu, Alina, Sjatskig, Jelena, de Maat, Moniek, Kluin, Jolanda, Leebeek, Frank, and Caliskan, Kadir

Abstract

Hemocompatibility-related adverse events (HRAEs), particularly gastrointestinal bleeding, remain a frequent complication after left ventricular assist device (LVAD) implantation. The current study sought to describe and analyze whether early (<60 days) postoperative von Willebrand factor (VWF) activity assays predict the risk of gastrointestinal bleeding and stroke. A prospective single-center study including 74 HeartMate 3 device recipients between 2016 and 2023 was undertaken. The postoperative trajectory of the VWF profile was analyzed using linear mixed-effect models and Cox models were used to quantify associations between an early postoperative dip (≤0.7) in VWF activity assay measurements and late outcomes. Preoperatively, the mean VWF:Activity (Act)/Antigen (Ag) and VWF:Collagen Binding (CB)/Ag ratios were 0.94 (95% confidence interval [CI] = 0.81–1.02) and 0.95 (95% CI = 0.80–1.03), respectively, decreasing to 0.66 (95% CI = 0.57–0.73) and 0.67 (95% CI = 0.58–0.74) within 40 days (p< 0.05). In patients with VWF:CB/Ag and VWF:Act/Ag ratios ≤0.7 significantly more gastrointestinal bleeding (hazard ratio [HR]: 2.53; 95% CI = 1.1–5.8, and HR: 3.7; 95% CI = 1.5–9.2, respectively) and hemorrhagic stroke events (HR: 3.5; 95% CI = 1.6–7.6 and HR: 4.9; 95% CI = 2.1–11.7, respectively) were observed throughout the entire late (>60 days) postoperative period. In patients with VWF:Act/Ag ratio ≤0.7 less ischemic stroke events were observed (HR: 0.11; 95% CI = 0.01–0.85). In conclusion, VWF:Act/Ag and VWF:CB/Ag ratios ≤0.7 in the early postoperative phase can be used as biomarkers to predict HRAEs during long-term LVAD support.

Published
2025
Full Text
View/download PDF

23. Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features

Author

Aukema, Sietse M., Croci, Giorgio A., Bens, Susanne, Oehl-Huber, Kathrin, Wagener, Rabea, Ott, German, Rosenwald, Andreas, Kluin, Philip M., van den Berg, Eva, Bosga-Bouwer, Anneke G., Hoogendoorn, Mels, Hoster, Eva, Bittmann, Iris, Nagel, Inga, Murga Penas, Eva M., Kreuz, Markus, Bausinger, Julia, Belder, Wilfried, Oschlies, Ilske, Dyer, Martin J. S., Jayne, Sandrine, Siebert, Reiner, and Klapper, Wolfram

Published
2021
Full Text
View/download PDF

26. Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry

Author

Kluin-Nelemans, Hanneke C., Reiter, Andreas, Illerhaus, Anja, van Anrooij, Bjorn, Hartmann, Karin, Span, Lambertus F. R., Gorska, Aleksandra, Niedoszytko, Marek, Lange, Magdalena, Scaffidi, Luigi, Zanotti, Roberta, Bonadonna, Patrizia, Perkins, Cecelia, Elena, Chiara, Malcovati, Luca, Shoumariyeh, Khalid, von Bubnoff, Nikolas, Parente, Roberta, Triggiani, Massimo, Schwaab, Juliana, Jawhar, Mohamad, Caroppo, Francesca, Fortina, Anna Belloni, Brockow, Knut, Zink, Alexander, Fuchs, David, Kilbertus, Alex, Yavuz, Akif Selim, Doubek, Michael, Mattsson, Mattias, Hagglund, Hans, Panse, Jens, Sabato, Vito, Aberer, Elisabeth, Niederwieser, Dietger, Breynaert, Christine, Várkonyi, Judit, Kennedy, Vanessa, Lortholary, Olivier, Jakob, Thilo, Hermine, Olivier, Rossignol, Julien, Arock, Michel, Gotlib, Jason, Valent, Peter, and Sperr, Wolfgang R.

Published
2020
Full Text
View/download PDF

27. Identification of Critical Slowing of Conduction Using Unipolar Atrial Voltage and Fractionation Mapping

Author

Ye, Ziliang, Ramdat Misier, Nawin L., van Schie, Mathijs S., Xiang, Hongxian, Knops, Paul, Kluin, Jolanda, Taverne, Yannick J.H.J., and de Groot, Natasja M.S.

Abstract

Ablation strategies targeting fractionated or low-voltage potentials have been widely used in patients with persistent types of atrial fibrillation (AF). However, recent studies have questioned their role in effectively representing sites of conduction slowing, and thus arrhythmogenic substrates.

Published
2024
Full Text
View/download PDF

28. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

Author

Voorwerk, Leonie, Slagter, Maarten, Horlings, Hugo M., Sikorska, Karolina, van de Vijver, Koen K., de Maaker, Michiel, Nederlof, Iris, Kluin, Roelof J. C., Warren, Sarah, Ong, SuFey, Wiersma, Terry G., Russell, Nicola S., Lalezari, Ferry, Schouten, Philip C., Bakker, Noor A. M., Ketelaars, Steven L. C., Peters, Dennis, Lange, Charlotte A. H., van Werkhoven, Erik, van Tinteren, Harm, Mandjes, Ingrid A. M., Kemper, Inge, Onderwater, Suzanne, Chalabi, Myriam, Wilgenhof, Sofie, Haanen, John B. A. G., Salgado, Roberto, de Visser, Karin E., Sonke, Gabe S., Wessels, Lodewyk F. A., Linn, Sabine C., Schumacher, Ton N., Blank, Christian U., and Kok, Marleen

Published
2019
Full Text
View/download PDF

29. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis

Author

Jawhar, Mohamad, Döhner, Konstanze, Kreil, Sebastian, Schwaab, Juliana, Shoumariyeh, Khalid, Meggendorfer, Manja, Span, Lambert L. F., Fuhrmann, Stephan, Naumann, Nicole, Horny, Hans-Peter, Sotlar, Karl, Kubuschok, Boris, von Bubnoff, Nikolas, Spiekermann, Karsten, Heuser, Michael, Metzgeroth, Georgia, Fabarius, Alice, Klein, Stefan, Hofmann, Wolf-Karsten, Kluin-Nelemans, Hanneke C., Haferlach, Torsten, Döhner, Hartmut, Cross, Nicholas C. P., Sperr, Wolfgang R., Valent, Peter, and Reiter, Andreas

Published
2019
Full Text
View/download PDF

32. Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM

Author

Lübke, Johannes, Schmid, Alicia, Christen, Deborah, Oude Elberink, Hanneke N. G., Span, Lambert F. R., Niedoszytko, Marek, Gorska, Aleksandra, Lange, Magdalena, Gleixner, Karoline V., Hadzijusufovic, Emir, Stefan, Alex, Angelova-Fischer, Irena, Zanotti, Roberta, Bonifacio, Massimiliano, Bonadonna, Patrizia, Shoumariyeh, Khalid, von Bubnoff, Nikolas, Müller, Sabine, Perkins, Cecelia, Elena, Chiara, Malcovati, Luca, Hagglund, Hans, Mattsson, Mattias, Parente, Roberta, Varkonyi, Judit, Fortina, Anna Belloni, Caroppo, Francesca, Brockow, Knut, Zink, Alexander, Breynaert, Christine, Leven, Toon, Yavuz, Akif Selim, Doubek, Michael, Sabato, Vito, Schug, Tanja, Hartmann, Karin, Triggiani, Massimo, Gotlib, Jason, Hermine, Olivier, Arock, Michel, Kluin-Nelemans, Hanneke C., Panse, Jens, Sperr, Wolfgang R., Valent, Peter, Reiter, Andreas, and Schwaab, Juliana

Abstract

•Serum chemistry profiling is of diagnostic and prognostic relevance based on easily accessible parameters.•Serum chemistry markers help to assess and quantify organ damage.

Published
2024
Full Text
View/download PDF

36. The future of valvular heart disease assessment and therapy

Author

Sengupta, Partho P, Kluin, Jolanda, Lee, Seung-Pyo, Oh, Jae K, and Smits, Anthal I P M

Abstract

Valvular heart disease (VHD) is becoming more prevalent in an ageing population, leading to challenges in diagnosis and management. This two-part Series offers a comprehensive review of changing concepts in VHD, covering diagnosis, intervention timing, novel management strategies, and the current state of research. The first paper highlights the remarkable progress made in imaging and transcatheter techniques, effectively addressing the treatment paradox wherein populations at the highest risk of VHD often receive the least treatment. These advances have attracted the attention of clinicians, researchers, engineers, device manufacturers, and investors, leading to the exploration and proposal of treatment approaches grounded in pathophysiology and multidisciplinary strategies for VHD management. This Series paper focuses on innovations involving computational, pharmacological, and bioengineering approaches that are transforming the diagnosis and management of patients with VHD. Artificial intelligence and digital methods are enhancing screening, diagnosis, and planning procedures, and the integration of imaging and clinical data is improving the classification of VHD severity. The emergence of artificial intelligence techniques, including so-called digital twins—eg, computer-generated replicas of the heart—is aiding the development of new strategies for enhanced risk stratification, prognostication, and individualised therapeutic targeting. Various new molecular targets and novel pharmacological strategies are being developed, including multiomics—ie, analytical methods used to integrate complex biological big data to find novel pathways to halt the progression of VHD. In addition, efforts have been undertaken to engineer heart valve tissue and provide a living valve conduit capable of growth and biological integration. Overall, these advances emphasise the importance of early detection, personalised management, and cutting-edge interventions to optimise outcomes amid the evolving landscape of VHD. Although several challenges must be overcome, these breakthroughs represent opportunities to advance patient-centred investigations.

Published
2024
Full Text
View/download PDF

37. Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial.

Author

Hoster, Eva, Delfau-Larue, Marie-Hélène, Macintyre, Elizabeth, Jiang, Linmiao, Stilgenbauer, Stephan, Vehling-Kaiser, Ursula, Salles, Gilles, Thieblemont, Catherine, Tilly, Hervé, Wirths, Stefan, Feugier, Pierre, Hübel, Kai, Schmidt, Christian, Ribrag, Vincent, Kluin-Nelemans, Johanna C., Dreyling, Martin, and Pott, Christiane

Published
2024
Full Text
View/download PDF

38. Data‐driven analysis of most common neurodegenerative dementias reveals atrophy patterns associated with overlapping cognitive symptoms.

Author

Venkatraghavan, Vikram, Bocancea, Diana I., den Braber, Anouk, Dubbelman, Mark A., Jiang, Chenyang, Coomans, Emma M., van Unnik, Annemartijn A. J. M., van Veen, Julia M.L., Ribberink, Marieke, Reijner, Niels, Saddal, Shalina, Mastenbroek, Sophie E, van Gils, Aniek M., Kluin, Caro M., de Leeuw, Diederick Martijn, Vromen, Eleonora M., Bekkers, Lotta, Georgallidou, Margarita, van der Landen, Sophie M., and Baumann, Janna M.

Abstract

Background: A precise understanding of the neuroanatomical basis of clinical manifestation of dementia is an important step for timely diagnosis. Dementia due to proteinopathies, such as Alzheimer's disease (AD), dementia with Lewy bodies (DLB), and Frontotemporal dementia (FTD), have different yet overlapping atrophy patterns which could account for their overlapping clinical presentations. To disentangle these relationships and facilitate timely differential diagnosis, we estimated distinct and overlapping atrophy patterns and associated them with cognitive deficits. Method: We included 1702 AD (age = 66.1±8.3), 319 FTD (age = 63.3±7.7), 213 DLB (age = 69.7±7.0), and 1330 subjective cognitive decline (SCD) (age = 59.8±9.0) participants from the Amsterdam Dementia Cohort. MRIs were processed with Freesurfer and outputs were manually checked. Scanner‐related bias in outputs was corrected using NeuroHarmony pipeline. Participants' cognition was evaluated using standardized neuropsychological tests. Z‐scores for cognitive domains of memory, executive functioning, attention, language, and visuospatial functioning were derived using SCD group as reference. We estimated distinct and overlapping atrophy patterns in each disease by computing odds ratio in each region, using SCD group as reference. Furthermore, we computed group‐wise Pearson partial correlation between the (sub‐)cortical measures and cognition while correcting for confounding effects of age, sex, and education level. Result: Atrophy in bilateral inferior temporal, and right hippocampus was more prevalent in AD and FTD patients than in DLB patients (Figures 1‐3). Temporal pole atrophy was more prevalent in FTD than in AD or DLB patients. Superior parietal and supra marginal atrophy was more prevalent in AD than in FTD or DLB patients. Bilateral hippocampus and amygdala atrophy associated with memory impairment in AD, whereas left hemisphere atrophy associated with memory impairment in FTD. Frontal atrophy associated with worse executive functioning and attention in FTD, but not in AD. Language deficit associated with left temporal lobe atrophy in both FTD and AD. Visuospatial dysfunction associated with parietal lobe atrophy in both AD and FTD. In DLB, we observed no significant correlation between atrophy and cognitive deficits. Conclusion: We identified distinct and overlapping atrophy patterns and associations of atrophy patterns with cognitive deficits in AD, FTD, and DLB. These data‐driven insights are crucial for accurate diagnosis and prognosis. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

43. Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

Author

Voorwerk, Leonie, Slagter, Maarten, Horlings, Hugo M., Sikorska, Karolina, van de Vijver, Koen K., de Maaker, Michiel, Nederlof, Iris, Kluin, Roelof J. C., Warren, Sarah, Ong, SuFey, Wiersma, Terry G., Russell, Nicola S., Lalezari, Ferry, Schouten, Philip C., Bakker, Noor A. M., Ketelaars, Steven L. C., Peters, Dennis, Lange, Charlotte A. H., van Werkhoven, Erik, van Tinteren, Harm, Mandjes, Ingrid A. M., Kemper, Inge, Onderwater, Suzanne, Chalabi, Myriam, Wilgenhof, Sofie, Haanen, John B. A. G., Salgado, Roberto, de Visser, Karin E., Sonke, Gabe S., Wessels, Lodewyk F. A., Linn, Sabine C., Schumacher, Ton N., Blank, Christian U., and Kok, Marleen

Published
2019
Full Text
View/download PDF

45. Automated FreeSurfer segmentation and visual quality control in 10,000 MRI scans from a large memory clinic cohort.

Author

Bocancea, Diana I., den Braber, Anouk, Jiang, Chenyang, Coomans, Emma M., van Unnik, Annemartijn A. J. M., van Veen, Julia M.L., Ribberink, Marieke, Reijner, Niels, Saddal, Shalina, Mastenbroek, Sophie E, van Gils, Aniek M., Kluin, Caro M., de Leeuw, Diederick Martijn, Vromen, Eleonora M., Bekkers, Lotta, Georgallidou, Margarita, van der Landen, Sophie M., Baumann, Jana M., Heuvelink, Joost, and Reus, Lianne M.

Abstract

Background: Automated image segmentation methods together with increasing computer power allow quantifying brain alterations in great detail in large neuroimaging datasets. The increasing size of data complicates visual quality control (QC), which is the gold standard. Increasingly often, research relies on automated QC methods. Here, we aimed to investigate the performance of automated FreeSurfer segmentation through visual QC in a large memory clinic cohort with more than ten thousand images, and to compare an automated QC measure to the visual QC. Method: 10,400 T1‐weighted MRI scans from the Amsterdam Dementia Cohort were segmented with FreeSurfer(v7.1). Quality control was performed using an adapted version of the Enigma QC protocol[https://doi.org/10.1038/ng.2250]. Twenty‐six individuals visually assessed cortical segmentations, rating each as "fail", "moderate", or "pass", identifying failure reasons and affected lobes. We investigated the error occurrence in failed or moderate quality scans, and whether segmentation failures depend on clinical diagnosis in a subset of 4990 baseline scans with most common diagnoses (i.e., SCD, MCI, AD, FTD, VaD and DLB). We compared an automated QC measure (i.e. median ± 3*IQR thresholded SurfaceHoles) with the visual QC output. Result: The majority (78.3%) of 10,400 cortical segmentations were rated as having "pass"‐quality, 16.2% were "moderate"‐quality and 5.4% segmentations were rated as "fail". Concordance between Automated QC and Visual QC was high for pass ratings(84%), but low for fail ratings(22.5%) (Table‐1). Within failed segmentations, most common reasons were processing errors(51.7%), image artifacts(14.3%) and underestimation(13.3%); for moderate ratings reasons were inclusion of meninges (47.8%) and underestimation of cortical thickness(33.2%) (Figure‐1). Stratified per diagnosis, segmentation failed in 2.3% of the SCD scans, 3% of MCI, 4.7% of DLB, 5.4% of AD, 7% of FTD and 14.5% of VaD. Further, we observed variation in affected lobes among diagnostic groups (Figure‐2b). Conclusion: The majority of scans passed visual QC, in high concordance with the automated QC. Images with moderate or failed quality, occurred more often in VaD and FTD. The most common mis‐segmentations were overestimation and underestimation of cortical thickness. This very large visually quality controlled data could be used as a benchmark to test future automated QC pipelines on. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Subcellular Localization of bcl-2 Protein

Author

de Jong, D., Prins, F., van Krieken, H. J. M., Mason, D. Y., van Ommen, G. B., Kluin, P. M., Capron, A., editor, Compans, R. W., editor, Cooper, M., editor, Koprowski, H., editor, McConnell, I., editor, Melchers, F., editor, Oldstone, M., editor, Olsnes, S., editor, Potter, M., editor, Saedler, H., editor, Vogt, P. K., editor, Wagner, H., editor, Wilson, I., editor, Potter, Michael, editor, and Melchers, Fritz, editor

Published
1992
Full Text
View/download PDF

50. The influence of cardiopulmonary bypass on pharmacokinetics and pharmacodynamics of anaesthetic drugs during cardiac surgery; a review with emphasis on sex differences.

Author

Beukers, Anne, Breel, Jenni, van den Brom, Charissa E., Saatpoor, Aryen, Kluin, Jolanda, Eleveld, Douglas J., Hollmann, Markus W., Hermanns, Henning, and Eberl, Susanne

Abstract

Cardiopulmonary bypass (CPB) can alter the pharmacokinetics and -dynamics of drugs, which can lead to altered plasma and effect site concentrations and consequently to incorrect dosing and thus adverse events. Females and males differ in their physiological body size and composition causing different pharmacokinetics and –dynamics of drugs. However, research in this field remains scarce, especially during CPB. The aim of this review is to summarise current knowledge on CPB-induced alterations in pharmacokinetics and -dynamics of anaesthetic drugs with an emphasis on sex differences. Nineteen articles were selected addressing pharmacokinetics and -dynamics: The studied drugs were propofol (8 articles), sevoflurane (3), fentanyl, remifentanil and sufentanil (2), alfentanil and lidocaine (1). Plasma concentrations fluctuated during CPB. Initiation of CPB resulted in haemodilution and hypothermia, leading to a decrease in total plasma concentration combined with an increase in unbound plasma concentrations. For propofol, sevoflurane and remifentanil, this implies that lower doses were required during CPB to achieve the same anaesthetic effect. For fentanyl, alfentanil and sufentanil, these fluctuations were clinically irrelevant. Standard pharmacokinetic models were unable to accurately predict plasma concentrations and showed over- or underprediction. Only five studies assessed sex as a potential confounder, and found that consideration of sex did not improve the ability of pharmacokinetic models to predict plasma concentrations during CPB. In conclusion, understanding the altered pharmacokinetics and -dynamics of drugs during CPB is crucial to ensure appropriate drug dosing in this high-risk population. Studies are needed to clarify sex-specific differences and optimise drug dosing strategies during CPB. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results